SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Takeda-6d

Item No. 35754

CAS Registry No.: 1125632-93-0
Formal Name: 2-chloro-3-(1-cyanocyclopropyl)-N-[5-[[2-[(cyclopropylcarbonyl)amino][5,4-b]pyridin-5-yl]oxy]-2-fluorophenyl]-benzamide
MF: $C_{27}H_{19}ClFN_5O_3S$
FW: 548.0
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Takeda-6d is supplied as a solid. A stock solution may be made by dissolving the takeda-6d in the solvent of choice, which should be purged with an inert gas. Takeda-6d is soluble in the organic solvent DMSO at a concentration of approximately 20 mM.

Description

Takeda-6d is a dual inhibitor of RAF kinases and VEGFR2.[1] It inhibits wild-type B-RAF, mutant B-RAF^{V600E}, and C-RAF (IC_{50}s = 12, 7, and 1.5 nM, respectively), as well as VEGFR2 (IC_{50} = 2.8 nM). Takeda-6d is selective for these kinases over a panel of 19 additional kinases (IC_{50}s = >1,000 nM) but does inhibit FGFR3, PDGFRα, and PDGFRβ (IC_{50}s = 22, 12, and 5.5 nM, respectively). It inhibits MEK and ERK1/2 phosphorylation in several colon cancer and melanoma cell lines expressing B-RAF^{V600E} when used at concentrations ranging from 100 to 1,600 nM, as well as inhibits VEGF-A-induced phosphorylation of VEGFR2 in VEGFR2-overexpressing KDR cells (IC_{50} = 0.53 nM). Takeda-6d (10 mg/kg) reduces tumor volume in an A375 melanoma mouse xenograft model.

Reference

1. Okaniwa, M., Hirose, M., Imada, T., *et al.* Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds. *J. Med. Chem.* **55(7)**, 3452-3478 (2012).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM